*All Times Shown are in Eastern Daylight Time*

8:30 am Virtual Coffee & Networking

Exploring the Emerging Consensus on Which Biomarker is the Most Useful for IPF Drug Development
Morning Plenary Moderator: Tushar Desai, Assistant Professor, Standford University Medical Center

9:00 am Providing an Update on IPF Biomarkers: Uncovering the Emerging Consensus on Which Biomarker Best Predicts Disease Progression to Help Maximize the Success of Your ILD Therapeutic in a Clinical Setting

  • Andrew Thorley Fibrosis Therapeutic Area Lead - OMNI Biomarker Development , Genentech

Synopsis

  • Reviewing findings from previous clinical trials
  • Emerging biological and digital biomarkers
  • Health equity in biomarker development

9:30 am Audience Discussion: Deep Dive Into the Role of Artificial Intelligence as Biomarkers for IPF: What do You Need to Know From a Technical, Ethical & Legal Perspective?

Synopsis

Kick off the first audience discussion of the day with a deep dive into understanding the potential for AI biomarkers for IPF. Is incorporating AI biomarkers worth the time, effort and cost? Join this session to analyze the relative merits and drawbacks of utilizing AI in your IPF research with other delegates and discuss the technical, ethical, and legal considerations you must make when deciding whether to use them.

10:00 am Early Disease Detection for Pulmonary Fibrosis: What Genetics & Protein Biomarker Studies Can Teach Us about IPF Disease Pathogenesis.

  • Gary Matthew Hunninghake Associate Professor of Medicine , Harvard Medical School

Synopsis

  • Why we should direct efforts towards early disease detection.
  • What genetic studies of early disease can teach us about IPF pathogenesis
  • What protein biomarker studies can teach us about IPF pathogenesis.
  • Planning for future interventional studies in early disease.

10:30 am Morning Break & Networking

Preclinical & Early Translational Track

Late Translational & Clinical Track

Deep Diving Into the Fibrotic Lung Microenvironment in the Context of IPF Therapeutics

Track Moderator: TBC

A Translational Journey: Investigating Endpoints & Imaging in the Context of IPF Drug Development

Track Moderator: TBC

11.00 Dissecting the Modified Lung Microenvironment in IPF Patients & Analyzing Which Biological Factors Linked to IPF Pathology to Manipulate Them for IPF Drug Development

Lisa Hazelwood, Principal Research Scientist Immunology & Fibrosis, AbbVie

11.00 Deep Diving into the Translational Pharmacology of Inhaled Small Molecules for the Treatment of Idiopathic Pulmonary Fibrosis

Rob Slack, Vice President & Head of Pharmacology, Galecto

11.30 Elucidating the Role of the Endothelium in the Context of IPF Drug Development

Rachel Knipe, Instructor in Medicine, Massachusetts
General Hospital

11.30 Revealing Radiology of Progressive Fibrosis

Mary Salvatore, Associate Professor Thoracic Radiology, Columbia University Medical Center

12.00 Investigating the Role of an Altered ECM Landscape in Idiopathic Pulmonary Fibrosis

Ulf Hedstrom, Senior Research Scientist, AstraZeneca

12.00 Spotlight on IPF Imaging: Examining Novel Imaging Modalities to Identify Fibrotic Progression in IPF Patients

Kristoffer Ostridge, Physician Director, AstraZeneca

12:30 pm Lunch & Networking

Exploring Emerging Therapeutics & Treatment Strategies for IPF

1:30 pm Dissecting the Mechanisms of Epithelial Dysfunction in IPF Patients & Revealing How This Relates to IPF Pathology

Synopsis

  • Review human genetic and biological data regarding changes in IPF epithelium
  • Highlight lessons learned from animal and cell culture models
  • Discuss the epithelium as a novel therapeutic target for reversing fibrosis

2:00 pm Understanding the Microbial Metabolic Drivers of Epithelial Cell Dysfunction in IPF

  • Philip Molyeanux Clinical Senior Lecturer in Interstitial Lung Disease, Imperial College London

Synopsis

  • Review data on the metabolic environment of the airways in IPF
  • Discuss how metabolites can effect epithelial cell and fibroblast function
  • Discuss how these pathways could be targeted

2:30 pm Afternoon Break & Networking

Discovering How to Design & Execute a Fool Proof Plan to Successfully Identify & Validate New Targets for IPF

3:00 pm Uncovering Targeted Drug Delivery to Improve Efficacy in IPF

  • Ruchi Gupta Senior Associate Director, Gilead Sciences

Synopsis

  • Understanding the importance of rapid organ delivery
  • Exploring reduced serum exposure in the context of IPF drug targeting
  • Exploring increased safety/reduced off target toxicity

3:30 pm Discovering Novel Approaches to Finding Targets for IPF

  • James Swaney Vice President - Fibrosis & Translational Biology , Lassen Therapeutics

Synopsis

  • Exploring novel approaches to finding targets for IPF
  • Understanding common mistakes biopharma make when identifying and validating new targets for IPF to learn how to avoid them
  • Looking through the crystal ball: What does IPF drug targeting look like in 2022?

4:00 pm Revealing Breakthrough Mitochondrial Science for IPF

Synopsis

  • Analyze how CohBar is harnessing the power of mitochondria peptides to target a wide range of chronic and age-related diseases associated with mitochondrial dysfunction, including IPF
  • Review CohBar’s clinical candidate, CB5138-3, in development for IPF which has demonstrated positive effects including reduction of fibrosis, inflammation, and collagen deposition.
  • Discuss other potential antifibrotic indications for CB5138-3

4:30 pm Next Generation Targeting in the Lung

Synopsis

  • New concepts for identifying and validating targets in the lung
  • Exploiting the dark side of your genome for next generation antifibrotic therapies in the lungs
  • Discovering your unique target profile

5:00 pm Conference End